The Guardian –
The Oxford/AstraZeneca Covid vaccine has efficacy of 90% in a small group who got a half-dose first, but only 62% in the majority, full trial data newly published in the Lancet has confirmed.
The results may create a quandary for regulatory bodies, which will have to decide on how the vaccine should be used if they approve it.
Oxford University and its partner, AstraZeneca, are seeking regulatory approval for their much-anticipated vaccine on the basis that it has 70% efficacy after pooling the results from trials in the UK and Brazil.
Read the full article: Oxford/AstraZeneca Covid vaccine has 70% efficacy, full trial data shows
